Abstract Body

Background: The quinoline-based compounds are promising leads for the development of clinically useful HIV-1 integrase (IN) inhibitors, however published studies with these quinoline-based compounds have highlighted the following deficiencies: i) the A128T mutation in IN has been shown to readily develop and confer marked resistance to this class of compounds; ii) the multifunctional nature of quinoline compounds to inhibit the IN-LEDGF/p75 binding and promote allosteric IN multimerization with similar IC50 values presents significant limitation for exploiting these inhibitors as investigational probes to study HIV-1 molecular biology. Methodology: We exploited the available X-ray crystal structures of quinoline compounds bound to HIV-1 IN catalytic core domain (CCD) to rationally modify existing quinoline compounds. In particular, we have compromised the quinoline moiety and made a series of modifications to enhance the inhibitor potency specifically for allosteric IN multimerization without significantly affecting the IN-LEDGF/p75 binding. Results: We have developed a new class of compounds that potently and selectively inhibits HIV-1 replication by allosterically modulating IN multimerization. In sharp contrast from quinoline compounds, our most promising multimerization selective inhibitor, PB-20 was about 60-fold more selective for IN-multimerization (IC50 of 89 nM) compared with IN-LEDGF/p75 binding (IC50 of 5,030 nM). The X-ray crystal structure of PB-20 bound to HIV-1 IN CCD elucidated structural basis for high selectivity of PB-20 for IN multimerization. PB-20 potently (EC50 of ~30 nM) inhibited HIV-1 replication when added to producer cells, whereas this compound was ~5,000-fold less effective in target cells (EC50 of ~50,900 nM). Such markedly reduced activity of PB-20 in target cells could be explained by the fact that PB-20 is not an effective inhibitor of IN-LEDGF/p75 binding during viral ingress, whereas the inhibitor could potently induce aberrant IN multimerization during the late stage HIV-1 replication. The A128T substitution, which is sufficient to effectively confer resistance to archetypal quinoline-based compounds, was not observed with PB-20. Instead triple substitution at the PB-20 binding site was identified as the main phenotype suggesting an increased genetic pressure by PB-20. These findings indicate the critical feasibility of our rational modification approaches to improve existing compounds. Conclusions: We provide a first demonstration of an HIV-1 IN inhibitor PB-20 that potently and selectively inhibits the late stage HIV-1 replication via selectively modulating the multimeric state of IN.